


















RESEARCH ARTICLE OPEN ACCESS

Extracellular Vesicles From Mesenchymal Stromal Cells Drive Muscle and Neuronal Regeneration Through TNF α Modulation

Agner Henrique Dorigo Hochuli^{1,2}  | Stefania D'Agostino^{1,2}  | Lucia Rossi^{1,2}  | Beatrice Auletta^{3,4}  | Leonardo Nogara^{5,6,7}  | Giovanni Tafuro^{7,8} | Giuseppe Germano⁹ | Alice Zaramella^{1,2}  | Paola Bisaccia^{1,2}  | Francesca Cecchinato^{4,10} | Carlo Biz¹¹  | Gabrielis Kundrotas¹²  | Pietro Ruggieri¹¹  | Alessandra Semenzato⁷  | Maurizio Muraca⁹  | Filippo Romanato¹³  | Piergiorgio Gamba^{1,2}  | Marcin Jurga¹² | Bert Blaauw^{5,6}  | Anna Urciuolo^{9,10}  | Michela Pozzobon^{1,2} 

¹Stem Cells and Regenerative Medicine Lab, Institute of Paediatric Research Città della Speranza, Padova, Italy | ²Department of Women's and Children's Health, University of Padova, Padova, Italy | ³Department of Industrial Engineering, University of Padova, Padova, Italy | ⁴Neuromuscular engineering lab, Institute of Paediatric Research Città della Speranza, Padova, Italy | ⁵Biomedical Sciences Department, University of Padova, Padova, Italy | ⁶Venetian Institute of Molecular Medicine (VIMM), Padova, Italy | ⁷Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy | ⁸Unired s.r.l., Padova, Italy | ⁹Institute of Paediatric Research Città della Speranza, Padova, Italy | ¹⁰Department of Molecular Medicine, University of Padova, Padova, Italy | ¹¹Department of Surgery, Oncology and Gastroenterology DiSCOG, Orthopaedic Clinic, University of Padova, Padova, Italy | ¹²EXO Biologics SA, Liège, Belgium | ¹³Department of Physics "Galileo Galilei", University of Padova, Padova, Italy

Correspondence: Michela Pozzobon (michela.pozzobon@unipd.it)

Received: 6 March 2025 | **Revised:** 8 January 2026 | **Accepted:** 19 January 2026

Keywords: 3D model | biological nanoparticles | functional muscle model | inflammation | microRNA | regenerative medicine | tissue engineering

ABSTRACT

Muscle defects caused by accidents, tumour resection and congenital malformations affect paediatric and adult patients. In this context, the neural-muscle regeneration potential of mesenchymal stromal/stem cells derived from extracellular vesicles (EV) has been demonstrated by our group and others, but the mechanism by which EVs act remains unknown. This work aimed to investigate the neural-muscle regeneration mechanism shown by EVs *in vivo* using three-dimensional (3D) multicellular *in vitro* models. We used (1) human muscle decellularised tissue (ECM) engineered with human muscle precursor cells (hMPC) together with macrophages THP-1 (M0) and (2) organotypic spinal cord from rat fetuses. We also studied neuroinflammation in 2D with primary microglia cells stimulated with lipopolysaccharide (LPS). Samples treated with good manufacturing practices (GMP)-grade EVs were assessed, combining functional analyses, protein and gene expression. In the functional muscle model, EVs protect the cells from death after damage, decreasing cCAS3 and stimulating cell proliferation. The protein array and gene results highlighted that EVs act through the downregulation of the TNF α factor. In parallel, in both neuroinflammation-induced microglia and organotypic spinal cord-damaged models, EVs regulated the neuroinflammation by inhibiting TNF α and promoting neural axon sprouting. In summary, EVs guard great potential for tissue regeneration by TNF α modulation, promoting muscle-neural regeneration.

This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2026 The Author(s). *Journal of Extracellular Vesicles* published by Wiley Periodicals, LLC on behalf of the International Society for Extracellular Vesicles.

1 | Introduction

The extracellular vesicles (EVs) are natural nanoparticles that carry a cargo of proteins, lipids and nucleic acids capable of modulating various cellular processes of the environment to achieve tissue regeneration (Welsh et al. 2024; Riazifar et al. 2017). In this context, EVs from mesenchymal stromal/stem cells have emerged as promising therapeutic agents for skeletal muscle repair (Sandona et al. 2020). Our previous study *in vivo* described the role of EVs in promoting the functional regeneration of the damaged muscle repaired with a decellularised muscle patch (Magarotto et al. 2021). Specifically, EVs showed a paramount role in promoting muscle strength, underlying the role of the nanoparticles supporting the regeneration of a functional neuromuscular system. Indeed, functional skeletal muscle regeneration requires correct reconstitution of the myogenic compartment and reinnervation, which is a critical factor to consider. However, the specific pathways involved in this regeneration process promoted by EVs remain unclear.

During the process of muscle loss and regeneration, it has been shown that one relevant pathway is the tumour necrosis factor- α (TNF α). TNF α is a cytokine that increases immune cell recruitment during inflammation and muscle damage, inducing muscular protein catabolism, myofibre apoptosis and impaired contractility (Collins and Grounds 2001; Juhas et al. 2014). In skeletal muscle, small non-coding molecules, such as microRNAs (miR/miRNA), play a pivotal role during the inflammatory process by repressing pro-inflammatory genes, such as TNF α . Indeed, microRNAs act post-transcriptionally by inducing messenger RNA (mRNA) degradation and translational repression (Chen et al. 2010). Some microRNAs in muscle have been described to repress inflammation, such as miR-145-5p (Li et al. 2018), and facilitate muscle regeneration via miR-21-5p (Ardite et al. 2012; Zanotti et al. 2015) and miR-206-5p (Liu et al. 2012; Dey et al. 2011).

Based on the significant challenges in fully understanding the mechanisms of EV action during muscle recovery and their influence on tissue regeneration, our study aimed to investigate specific pathways through which EVs may promote muscle and neural repair. To do so, we investigated the mechanism of action of EVs by using three-dimensional (3D) *in vitro* models in which the muscle or the neural compartment could be studied at molecular levels.

In 3D environments that mimic the muscle niche, scaffolds play a pivotal role in contemporary tissue engineering, serving as essential platforms to guide cellular growth and differentiation (Nikolova and Chavali 2019; Liu et al. 2007). Their emergence has ignited groundbreaking possibilities for tissue regeneration and repair (O'Brien 2011; Han et al. 2020). These scaffolds are composed of a wide variety of materials, ranging from synthetic polymers to naturally derived substances such as collagen, elastin, hyaluronic acid and decellularised tissue (Magarotto et al. 2021; Chen et al. 2022; Chan and Leong 2008; Rey and St-Pierre 2019).

Decellularisation of tissues is a process that seeks to exploit the structural strength of the extracellular matrix (ECM) while mitigating the challenges associated with immune responses

arising from residual cellular components (Neishabouri et al. 2022; Riis et al. 2020). The ECM, composed of intricate networks of proteins and glycosaminoglycans, facilitates mechanical support, providing growth factors essential for cellular interactions, differentiation and tissue regeneration (Godoy-Guzmán et al. 2018; Wang et al. 2010). In the realm of skeletal muscle, the ECM transcends its structural function to become a conduit for mechanical signalling, cell modulation and regenerative cues (Takahashi et al. 2018). It has already been demonstrated that scaffolds of natural materials, such as decellularised skeletal muscle ECM, become a tissue-like environment when engineered with muscle cells and macrophages (Juhas et al. 2018; Quarta et al. 2017). The latter are paramount to sustain muscle regeneration after injury (Juhas et al. 2018).

Thus, we used decellularised skeletal muscle ECM engineered with muscle cells and macrophages as a muscular model to investigate the effect of EVs *in vitro*. Simultaneously, we examined the potential of EVs to inhibit neuroinflammation in microglial cells *in vitro* (Zong et al. 2021). Additionally, we assessed the ability of EVs to promote neural axon sprouting and their neurotrophic effects on *in vitro* organotypic 3D spinal cord cultures, as reported in the literature (Raffa et al. 2020). By developing such 3D multicellular *in vitro* models that closely mimic the complex microenvironment of muscular and neuronal compartments, we explored the hypothesis that EVs can modulate *in vitro* cellular behaviour and key pathways, such as TNF α , which are critical for inflammation resolution and tissue regeneration. This research provides valuable insights into the regenerative potential of EVs, paving the way for advanced therapeutic strategies targeting muscle degeneration and related disorders.

2 | Materials and Methods

2.1 | Human Muscle Precursor Cells Isolation

Human muscle biopsies (*peroneus longus* ($n = 5$) and *tibialis anterior* ($n = 5$)) were collected after ethical committee approval (Azienda Ospedaliera of Padova, Prot. N° 2682P). These tissue samples were selected for decellularisation or isolation of human muscle progenitor cells (hMPCs). hMPCs were isolated, according to Franzin et al. (2016). Briefly, the biopsies were disinfected with betadine and two Phosphate-buffered saline (PBS) (Gibco) rinses. The biopsies were minced and incubated with 0.2% (w/v) of collagenase type I (Sigma-Aldrich) for 90 min at 37°C. The digested product was centrifuged with washing medium (Dulbecco's Modified Eagle Medium (DMEM) (1×) 1 g/L glucose (+) L-glutamine (+) pyruvate (Gibco) containing 20% foetal bovine serum (FBS) (Thermo Fisher Scientific) and 1% Penicillin-Streptomycin (Pen-Strep) (Thermo Fisher Scientific) and homogenate with serological pipette, then centrifuge at 300 × g for 10 min. The pellet was resuspended with 2 mL of 0.05% Trypsin-EDTA (Gibco) and incubated for 60 min at 37°C. The digestion product was collected, and Trypsin-EDTA was inactivated with 10 mL of washing medium; the suspension was filtered twice through 70 μ m (Sarstedt) and 40 μ m (Sarstedt) cell strainers, then centrifuged at 300 × g for 10 min. The supernatant was discarded, and the pellet was resuspended with Red Blood Lysis buffer (Thermo Fisher Scientific) for 3 min, then 10 mL of washing medium was added, followed by centrifugation at

300 × g for 10 min. The pellet was resuspended in proliferative medium (DMEM (1×) 1 g/L glucose (+) L-glutamine (+) pyruvate containing 20% FBS, 10⁶ M dexamethasone (Sigma Aldrich), 10 ng/mL recombinant mouse Fibroblast growth factors (FGF) basic protein (R&D Systems), 10 µg/mL insulin (Insuman Rapid 100 UI/mL, Sanofi Aventis) and 1% Pen-Strep) and seeded in non-tissue culture (NTC) 6-well plate (Falcon). The cells were stored in an incubator at 37°C in a humid atmosphere with 5% CO₂. The medium was changing every 2/3 day. Cells were characterised as described by Trevisan et al. (2019). The percentage of CD56+ cells was determined by flow cytometry using Cytoflex (Beckman Coulter), staining cells with anti-human CD56-PE clone B159 (BD Biosciences Pharmingen).

2.2 | Human Monocytes

THP-1 cells were purchased by ATCC (#TIB-202 ATCC) and were cultured following the manufacturer's guidelines, using RPMI 1640 (Gibco), 10% FBS (Thermo Fisher Scientific), 1% L-Glutamine (Gibco) + 1% Pen-Strep (Thermo Fisher Scientific). THP-1 were differentiated into macrophages (M0) using 50 ng/mL phorbol 12-myristate 13-acetate (Sigma-Aldrich) for 24 h. The medium was changed every 2/3 day.

2.3 | Two-Dimensional (2D) Co-Culture of hMPCs and THP-1 Cells

hMPCs and macrophages from THP-1 were co-culture following previous studies (Juhas et al. 2018), following a ratio of 70:30. The co-culture started seeding hMPCs and THP-1 into a 24-well plate (non-tissue culture, Falcon) in the proliferative medium for 48 h, followed by a differentiation medium for 5 days. The medium was changed every 2/3 days.

2.4 | Induction of Skeletal Muscle Damage and Treatments

To induce skeletal muscle loss-like damage, the medium was replaced with a cardiotoxin (CTX) medium, consisting of a differentiation medium supplemented with 0.4 µM cardiotoxin (Latoxan). This was followed by a 24-hour culture period. Subsequently, the medium was replaced with differentiation medium again, and the following treatments were administered: damaged CTX samples were treated with three doses of 1 × 10⁹ EVs: the first dose was given 24 h after CTX damage, with subsequent doses administered at 24-hour intervals (EVs group); while the ECMs were treated with one dose of 1.25 µM TNFα inhibitor SPD304 (Merck) (TNFα group) after 24 h of the CTX damage. The samples were analysed 5 days after the CTX-induced damage. The Pan Caspase inhibitor Q-VD-Oph (Merk) was also assessed. As a control, hsa-miR-145-5p inhibitor (MedChem) was loaded into Lipofectamine RNAiMAX (Invitrogen) following the manufacturer's guidelines. Summarising, 6 pmol of synthetic hsa-miR-145-5p inhibitor was diluted in 100 µL of Opti-MEM I Reduced Serum Medium (Gibco) and gently mixed. Then, 1 µL of Lipofectamine RNAiMAX was added to the mixture, followed by gentle mixing and incubation at room temperature (RT) for 15 min to allow complex formation. MiR-145-5p inhibitor loaded

into Lipofectamine was delivered into the ECM 24 h after CTX damage, with a total of three doses administered at intervals of 3, 6 and 24 h.

2.5 | EVs Production and Characterisation

EVs were manufactured using mesenchymal stromal cells (MSC) isolated from human umbilical cord tissue and supplied by EXO Biologics SA (Liège, Belgium). The biological material was supplied by a certified Biobanks (Biothèque Hospitalo-Universitaire de Liège and UZA in Antwerpen) registered at the Belgian Federal Agency for Medicines and Health Products in accordance with the Belgian Law.

EVs were produced under a GMP-compliant process which underwent minor modifications from the previous work described in Bisaccia et al. (2024). The modifications included a process scale-up bioreactor for large-scale production and the process scale-down production for small-scale non-clinical experiments. For this study, EVs size distribution and concentration were measured using the ZetaView (Particle Metrics) Nanoparticle Tracking Analysis (NTA) instrument. The MACSPlex exosome kit (Miltenyi Biotech) was used to identify EV antigen markers. The surface membranes and their sizes were analysed by cryo-TEM as described by Bisaccia et al. (2024). EVs activity was measured using a GMP potency assay developed based on what was previously described in assay (Malvicini et al. 2022).

2.6 | EV Total RNA Isolation and miRNA Sequencing

The miRNA expression profile of EVs was determined by small RNA sequencing (GIGA Research Center, University of Liege). miRNAs were isolated by miRNeasy Mini Kit (Qiagen), quantified by Ribogreen (Life Technologies) and qualified by Agilent 2100 Bioanalyzer system using Eukaryote Total RNA Pico chip. A small RNA library construction was performed using the QIAseq miRNA Library Kit (Qiagen). Library pre-sequencing QC was performed using the QIAxcel DNA Screening Kit (Qiagen), and library quantification was evaluated with qPCR. Small RNA sequencing was conducted by Novaseq 6000 (Illumina) using the Novaseq 6000 S1 Reagent Kit (100) single-read standard workflow. The small RNA sequencing data processing and analyses, including filtering, trimming, mapping, quantification of the sequenced reads, and normalisation of the resulting read counts, were carried out by BioLizard NV (Belgium) using a Nextflow pipeline (<https://nf-co.re/smrnaseq/1.1.0>).

2.7 | Extracellular Matrix Decellularisation

We tested different decellularisation approaches using a detergent-enzymatic treatment (DET) and non-detergent-enzymatic treatment (NDET) to establish the optimal protocol for decellularised human muscle ECM. All biopsies (*from tibialis anterior and peroneus longus*) were cut into pieces weighing 50 mg each, following the dimensions of 6 × 4 × 3 mm³. An established protocol was employed to decellularise healthy muscle tissue as

previously described using DET (Piccoli et al. 2017). All fresh-cut biopsies were washed overnight (ON) in water with 3% Pen-Strep (Gibco) at 4°C. Within this methodological framework, each biopsy was thoughtfully allocated to distinct experimental groups, thus facilitating a comprehensive evaluation of various decellularisation techniques. Control Group: In this regard, the biopsies were deliberately left untreated, constituting the control group and preserving the tissue. DET—Sodium deoxycholate (SDC) decellularisation group: The samples were maintained for 4 h at 37°C under agitation exposure to 4% sodium deoxycholate (Sigma-Aldrich) followed by a subsequent incubation in a solution comprising 2000 KU DNaseI (Sigma-Aldrich) resuspended in 1 M NaCl (Sigma-Aldrich) for 3 h, and the samples were washed with sterile MilliQ water supplemented with 3% Pen-Strep (Gibco) ON. These two steps were conducted under agitation at RT. This protocol was iterated over three DET cycles to ensure the absolute decellularisation of the tissue. Non-detergent-enzymatic treatment (NDET)—Latrunculin B decellularisation (LB) group: A detergent-free approach was implemented by substituting 4% SDC with Latrunculin B (Sigma-Aldrich), resuspended at concentrations of 50 or 500 nM in high glucose DMEM at 37°C for 4 h under agitation. Follow for 2000 KU DNaseI resuspended in 1 M NaCl for 3 h at RT under agitation. The samples were washed in sterile MilliQ water supplemented with 3% Pen-Strep ON at 4°C. This detergent-free protocol was performed for two cycles.

2.8 | Decellularised ECMs DNA Removal Analysis

The effectiveness of decellularisation was assessed by analysing DNA extracted from tissues treated with both decellularisation methods (SDC and LB) and comparing it to fresh tissues (positive control). DNA extraction was performed using the DNeasy Blood & Tissue Kit (Qiagen), following the manufacturer's protocol. The results of the analysis of the concentration of the DNA are presented as a fold change.

2.9 | Texture Analysis

The compression tests were performed as described by Saggiaro et al. (2022). Decellularised ECMs were placed in 200 µL hydrogel blocks containing cells and proteins, utilising a Texture Analyzer TMS-Pro from Food Technology Corporation (Sterling, Virginia, USA). The testing apparatus was equipped with a 10N load cell and featured a cylindrical stainless-steel probe with a 1 cm diameter. The hydrogel specimens were positioned atop a pristine, level aluminium base and all experiments were executed in triplicate under RT conditions. Through vertical displacement, the probe compressed each sample to a depth of 1 mm at a constant rate of 60 mm/min, retracting to its initial point of contact with the sample. The pre-test velocity was set at 30 mm/min, while the test speed and post-test velocity remained consistent at 60 mm/min. The Texture Lab Pro software (version 1.1) facilitated data acquisition and visualisation. The force requisitioned for sample compression was recorded as a function of the probe's displacement. Analysing the resultant load (N) versus displacement (mm) curve, the following essential parameters were derived: Hardness: Characterised by the positive peak on the curve, denoting the maximum Newton (N) force required to compress

the sample. Consistency: Quantified as the area beneath the positive curve (N*mm), representing the total work performed by the sample against deformation. Stiffness: Assessed as the slope during the compression phase (N/mm²), offering further insights into the sample's firmness and deformability.

2.10 | Decellularised ECM Collagen Network Analysis

The methodology for collagen network analysis was adapted from Todesco et al. (2022). Following the protocol, decellularised ECMs underwent fixation in 4% Paraformaldehyde (PFA) (Bioptica) for 20 min and were subsequently stored in PBS (Sigma Aldrich). Two-photon microscopy was employed to assess the impact of the decellularisation procedure on the structural integrity of key ECM components, specifically collagen and elastin, by quantifying the second harmonic generation (SHG) and elastin autofluorescence signal (AutoF). The SHG and elastin imaging were conducted using a custom-developed multiphoton microscope (Filippi et al. 2018). Image acquisition occurred at a fixed magnification with an Olympus 25X water immersion objective. Signals were averaged over 70 consecutive frames. Z-stacks were recorded for both groups. Quantitative analysis of the raw uncompressed images was performed using OrientationJ Plugin for ImageJ software (Schindelin et al. 2012). Coherency (C) was calculated for collagen and elastin to assess the local dominant fibres orientation within the Z-stack images (Rezakhaniha et al. 2012). The resulting parameter ranged between 0 and 1, where values closer to 0 indicate isotropy (absence of dominant orientation), and values closer to 1 indicate anisotropy (presence of dominant orientation). The organisation and distribution of fibers were visually represented through fast Fourier transform (FFT) analysis, providing a graphic representation of the coherency level. Transform-based texture analysis techniques were applied to convert the image based on spatial frequency properties of pixel intensity variations, extracting textural characteristics from the image. An elliptic shape in the representation suggested highly oriented fibres in a single direction, while a circular shape indicated fibres spreading in all directions (Rezakhaniha et al. 2012; Wu et al. 2011).

2.11 | Immunohistochemistry

Human healthy muscle tissues were fixed in 4% PFA, dehydrated in a sucrose gradient (10%, 15% and 30%, Sigma-Aldrich) and included in Killik cryostat embedding medium (Bio-Optica). Samples were stored at -80°C until cut on 7 µm slices using Leica CM1520 cryostat. Cryosections were stained for Alcian Blue (Bio-Optica) following the manufacturer's guidelines.

2.12 | Immunofluorescence (IF)

For whole-mount staining, the ECMs were fixed with 4% paraformaldehyde (PFA) for 2 h at RT for the immunofluorescence analysis. Whole mount staining samples underwent permeabilisation (PBS + 1% Bovine Serum Albumin (BSA) (Sigma-Aldrich) + 0.5% Triton (Sigma-Aldrich)) under agitation (70 rpm) for 2 h at RT and were subsequently rinsed with wash solution (PBS + 0.05% Tween 20(Sigma-Aldrich)). The samples

TABLE 1 | Primary and secondary antibodies are used for immunofluorescence analysis.

Antibodies	Dilution	Incubation condition
Rabbit anti-laminin (Sigma-Aldrich)	1:200	1 h at 37°C
Mouse anti-myosin heavy chain (MHC, R&D Systems)	1:100	2 h at 37°C
Rabbit anti-Ki67 (Abcam)	1:100	1 h at 37°C
Rabbit anti CAS3 (Cell Signaling Technology)	1:300	ON at 4°C
Mouse anti-embryonal myosin heavy chain (MYH3, Santa Cruz Biotechnology)	1:100	1 h at 37°C
Chicken anti-Rabbit IgG Secondary Antibody, Alexa Fluor 488 (Invitrogen)	1:200	1 h at RT
Goat anti-Mouse IgG Secondary Antibody, Alexa Fluor 594 (Invitrogen)	1:200	1 h at RT
Phalloidin (Abcam)	1:2000	ON at 4°C
DAPI (Sigma-Aldrich)	1:2000	ON at 4°C

were then incubated with primary antibodies (refer to Table 1) for 2 days at 4°C. Afterwards, the samples were rinsed with wash solution and incubated with secondary antibodies (refer to Table 1) for 2 h at 37°C. Cell nuclei were stained with Hoechst (Thermo Fisher Scientific). Imaging was performed using a Leica Confocal Zeiss LSM800 Airyscan. For cryosection samples, they were dehydrated in a sucrose (Sigma-Aldrich) gradient ranging from 10% to 15%, culminating in 30%. Subsequently, samples were embedded in OCT and slowly frozen. The cryosection samples were stored at -80°C for 7 µm sections and staining. Cryosection slides were permeabilised with PBS containing 0.5% Triton X-100 (Sigma-Aldrich) for 20 min, followed by three rinses with PBS for 5 min each. Subsequently, sections were blocked with PBS containing 1% BSA for 20 min and rinsed thrice with PBS for 5 min each. The slides were then incubated with primary and secondary antibodies, as described in Table 1. The slides were mounted with Fluoroshield mounting medium (Sigma-Aldrich). Leica B5000 camera was used for imaging.

2.13 | Myogenic Index

Fixed cells were stained with mouse anti-myosin heavy chain (MHC) (Table 1). After washing, a secondary antibody was then applied (Table 1). Cells were washed and counterstained with DAPI (Sigma-Aldrich) to visualise nuclei. Imaging was performed using a Leica B5000 camera. The myogenic index was determined by calculating the ratio of myofibres (stained for MHC) containing three or more nuclei to the total number of nuclei (Franzin et al. 2016). Images were taken in 20× magnification for each sample.

2.14 | Recellularisation

Before induction, THP-1 monocytes were seeded in NTC 24-well plate with complete growth medium (RPMI 1640 + 10% FBS + 1% L-Glutamine, + 1%Pen-Strep) supplemented with 50 ng/mL PMA for 24 h (Sigma Aldrich). ECMs were cut into 6.5 × 3 × 4 mm pieces, and each piece was embedded in FBS at 37°C for 1 h; meanwhile, the cells were prepared for the injection of 2 × 10⁶ hMPCs or 1.4 × 10⁶ hMPCs + 6 × 10⁵ THP1-derived macrophages resuspended in 20 µL of 10% Matrigel (Corning) in proliferation medium using a microinjector (World Precision

Instruments, Sarasota, USA). Subsequently, the recellularised ECMs were transferred to an 8 µm-pore transwell (Sarstedt) within a standard 24-well plate and incubated at 37°C for 3 h without medium. Following this, 800 µL of hMPCs proliferative medium (DMEM (1×) 1 g/L glucose (+) L-glutamine (+) pyruvate containing 20% FBS, 10⁻⁶ M dexamethasone (Sigma Aldrich), 10 ng/mL recombinant mouse FGF basic protein (R&D Systems), 10 µg/mL insulin (Insuman Rapid 100 UI/mL, Sanofi Aventis) and 1 % Pen-Strep was added to the basal side of the transwell and 200 µL to the apical side. This proliferative medium was renewed every 2 days for 4 days. After 5 days of culture, the medium was changed to a differentiation medium composed of MEMalpha, (+) L-glutamine, (+) ribonucleosides, (+) deoxyribonucleosides, (-) ascorbic acid (Thermo Fisher Scientific) containing 2% horse serum (Thermo Fisher Scientific), 10 µg/mL insulin (Insuman Rapid 100 UI/mL, Sanofi Aventis) and 1% Pen-Strep (Thermo Fisher Scientific) for 8 days.

2.15 | Tension Resistant Analysis

Tissue functionality was performed at the 13-day time point (5 days of proliferative medium and 8 days of differentiation medium) in samples of ECM engineered with hMPC and Macrophages, before (*n* = 3) and after CTX (*n* = 3). The tissue was fixed using metal clips to a force transducer (KG Scientific Instruments, Heidelberg, Germany), and the length was carefully adjusted to balance passive and active tension; the experiment was carried out in a bath of Ringer solution (119.8 mM NaCl, 25 mM NaHCO₃, 11.1 mM glucose, 4.7 mM KCl, 3.15 mM MgCl₂, 2.5 mM CaCl₂, 1.3 mM NaH₂PO₄) set at 25°C. Sample contraction was electrically triggered by a Grass S11 stimulator applying 50 V at increasing frequencies (single stimulus, 25, 50, 75, 100, 150 and 200 Hz) for 2 s, while tension was recorded by the force transducer.

2.16 | Total RNA Isolation and miRNA Enrichment

ECM samples were snap-frozen in liquid nitrogen and stored at -80°C until analysis. For RNA extraction, samples were embedded in 1 mL of TRIzol reagent (Invitrogen). Stainless steel beads were used to dissociate ECM samples using the Tissue Lyser

TABLE 2 | Primer used for microRNA qRT-PCR.

microRNA	Catalogue number
hsa-miR103a-3p	YP00204063
hsa-miR145-5p	YP00204483
hsa-miR21-5p	YP00204230
hsa-miR206-5p	YP00206073

II (Qiagen). Total RNA was isolated from the homogenised tissue following the manufacturer's protocol. RNA quality was quantified and assessed using Nanodrop 2000 (Thermo Scientific). The retro transcription step was performed using the Applied Biosystem Reverse Transcription Kit (Applied Biosystems) following the manufacturer's guidelines. The miRCURY LNA miRNA PCR Assay (Qiagen) was used, following the manufacturer's protocol to isolate small RNA molecules from large RNA fragments. The isolated small RNA was stored at -80°C .

2.17 | Quantitative Real-Time PCR (qRT-PCR)

The SYBR Green PCR Master Mix (Applied Biosystems) and miRCURY LNA SYBR Green PCR Kit (Qiagen) were used to confirm the mRNA and miRNA expression changes, respectively. The relative expression of each target miRNA: hsa-miR21-5p, hsa-miR206-5p and hsa-miR145-5p (Qiagen) (Table 2) in tissues was relatively calculated to the housekeeping gene provided by Qiagen (YP00204063). For qRT-PCR, the expression of each target mRNA was calculated relative to GAPDH (Table 3). The RT-qPCR was performed using the Applied Biosystems QuantStudio 5 Real-Time PCR.

2.18 | Cytokines Analysis

Cytokine profiling was evaluated using the Quantibody Human Cytokine Array 1 (QAH-CYT-1) and Quantibody Rat Cytokine Array 1 (QAR-CYT-1), both from RayBiotech. The assays were carried out according to the manufacturer's instructions. Protein extraction from samples was performed using a Tissue Lyser (Qiagen). Samples were shaken at 30,000 rpm for 3 min in the presence of stainless-steel beads and RIPA buffer (pH 7.6) composed of 10 mM Tris-HCl (pH 8.0), 1 mM EDTA, 0.5 mM EGTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, 140 mM NaCl, and protease inhibitors (Roche). The extracted proteins were quantified using the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific). For each sample, 100 μL of total protein, at concentrations ranging from 50 to 500 $\mu\text{g}/\text{mL}$, was prepared and normalised per the manufacturer's guidelines. Before analysis, the slides were blocked with a sample buffer for 30 min. Tear samples and standards were applied to the arrays and incubated ON at 4°C . After incubation, the slides were washed with a proprietary buffer and treated with a detection antibody for 2 h at RT. This step was followed by additional washing and incubation with Cy3-equivalent dye-conjugated streptavidin for 1 h at RT. The slides were rewashed, thoroughly dried, and scanned using the GenePix 4000B scanner with the Cy3 excitation profile. Cytokine concentrations (pg/mL) were normalised and

determined by comparing the mean fluorescence intensity (MFI) to a standard curve generated with the kit's materials. Each standard curve was evaluated for outliers and adjusted to ensure linearity ($R^2 \geq 0.8$).

2.19 | Primary Microglia Cells *In Vitro* and EV Administration

Primary microglial cells CD11b^+ were isolated from pooled BALB/c adult mouse brains, cultured in a 96-well plate for 6 days, and further tested at the Charles River Laboratories (The United Kingdom). On day 6, lipopolysaccharide (LPS) (50 ng/mL) as an inflammation inducer, prednisolone (50 ng/mL) as an inhibitor control + LPS and EVs (3×10^8 , 8×10^8 , 3×10^9 particles per well) + LPS were added for 16 h. Unstimulated cells were used as controls. Morphology was assessed by IncuCyte System (Sartorius) by taking phase images every 2 h during the 16 h of incubation. Cell viability was assessed by quantitative colorimetric cell title growth assay (Promega). On day 7, media were collected to quantify $\text{TNF}\alpha$ cytokine released in the supernatant, using ELISA assay.

2.20 | Spinal Cord Isolation, EV Administration and miR-145-5p Inhibition

Sprague Dawley rats (250–350 g) were used, and all the procedures were carried out in accordance with Animals (Scientific Procedures) Act 1986. E14 fetuses were obtained from pregnant Sprague Dawley rats (Charles River Laboratories) to acquire spinal cord cultures. The procedures performed on animals were in accordance with Italian National laws and policies (D.L. n. 26, 14 March 2014), following the guidelines established by the European Community Council Directive (2010/63/EU), and with the approval of the Italian Ministry of Health (authorisation number: D2784.N.I6Q). The isolated spinal cords (SpC) from rat foetus E14 were cut into three sections (apical, central, and caudal; $\sim 1 \times 1 \times 2 \text{ mm}^3$) and cultured within 5 μL drop of 100% Matrigel Growth Factor Reduced (Corning) cast onto a glass coverslip. Matrigel droplet was polymerised for 10–15 min at 37°C prior to media supplementation. Samples were then cultured in Neurobasal medium (Gibco), B-27 supplement (Gibco) 1X, 2% Horse serum (Gibco), 0.5 mM GlutaMAX Supplement (Gibco), 25 μM 2-Mercaptoethanol (Gibco), 25 μM L-Glutamic acid (Sigma), Gentamicin/Amphotericin (Gibco), 10 ng/mL ciliary neurotrophic factor (CNTF, PeproTech) and 10 ng/mL glial-cell-line-derived neurotrophic factor (GDNF, Peprotech). SpC sections were divided into two groups: untreated and EV-treated. EVs were administered straight after the sectioning, 6 and 24 h after the first dose (3 doses of 1×10^9 each). For miR-145-5p inhibition, miR-145-5p inhibitor (MedChemExpress) was loaded in Lipofectamine (Invitrogen) as described above. The miR-145-5p inhibitor loaded into Lipofectamine was administered immediately after spinal sectioning and seeding into Matrigel, with a second dose administered six hours later. SpC were maintained in culture for 24 or 48 h, as specified in the result section

TABLE 3 | Primer used for mRNA qRT-PCR.

Gene	Accession number	Primer forward	Primer reverse	Amplicon size
hTNF α	NM_000594.4	ACCTCCTCTCTGCCATCAAG	ATCCCAAAGTAGACCTGCCC	187
hNOTCH1	NM_017615.5	AGACTATGCCTGCAGCTGTG	GGCACGATTTCCCTGACCA	167
hMYOD	NM_002478.5	CAGCCGCGGCTCCAAGTCT	TTCCCGGGCCTGGGTTGCT	126
hARG1	NM_001369020.1	TCACCTGAGCTTTGATGTCG	CTGAAAGGAGCCCTGTCTTG	134
hNOS2	NM_000625.4	TCCCGAAGTTCTCAAGGCAC	TTCTTACTGTGGGGCTTGC	93
hTRAF2	HM991672.1	GCTGACTTGGAGCAGAAGGT	CAGGTAGATACGCAGGCACAT	183
hNFK β	NM_003998.4	ACTGTGAGGATGGGATCTGC	GCCTCTGTTCATTCGTGCTTC	130
hGAPDH	NM_001357943.2	CCAGAACATCATCCCTGCCT	CCTGCTTACCACCTTCTTG	185
rTnf α	NM_012675.3	ATGGGCTCCCTCTCATCAGT	GCTTGGTGGTTTGCTACGAC	106
rNeurofilament	NM_031783.2	GCCGCCAAGAATATGCAGAA	GCTTCGATCTCCAGGGTCTT	158
rGapdh	NM_017008.4	AACGACCCCTTCATTGACCT	GCTTCCCATTCTCAGCCTTG	100

2.21 | Quantification of Neuronal Axon Projections

The length of the axon projection was quantified using the NeuronJ plugin on ImageJ software (version 1.57t—MacOS, California, USA). Brightfield images of each condition were converted to an 8-bit grayscale, and then the length and the number of the axons were measured with the tracing tool. The results are expressed in mean with standard deviation.

2.22 | Live Imaging Analysis

All the analyses in live imaging were performed using a Leica M205 FCA stereomicroscope equipped with PLANAPO 1.0X objective, with an acquisition rate of 9 frames per second.

For calcium experiments, whole-mount samples were treated with EVs for 48 h, and controls were analysed with Fluo-4-AM (Invitrogen) following the protocol instructions. Briefly, after PBS wash, samples were incubated with 20 μ M Fluo-4-AM (Invitrogen), 5 μ L/mL Pluronic F-127 (Thermo Fisher Scientific), and 12.5 μ L/mL sulfinpyrazone (Sigma-Aldrich) in serum-free cell medium for 30 min at 37°C and 5% CO₂. Samples were then accurately washed by Neurobasal media (Life Technologies) and subjected to live imaging analysis. Samples were stimulated with glutamate (Glu, Sigma-Aldrich) at the final working concentration of 10 μ M. For calcium $\Delta F/F_0$ calculation, ≥ 6 regions of interest (ROIs) per sample with a size of 20 μ m (Riazifar et al. 2017) were used for calcium flux analysis to identify baseline (before neurotransmitter stimulation, F_0) and maximum (after neurotransmitter stimulation, F_{peak}) fluorescence intensity values. Measure plugin of ImageJ was used to quantify the $\Delta F/F_0$ on arbitrarily extracted.lif frames from LAS X Leica software.

For calcein staining, EVs were incubated with a working solution of 3 μ M calcein in serum-free cell medium for 30 min at 37°C and 5% CO₂ and washed with PBS before imaging. EVs were then accurately washed with Neurobasal media added to the organotypic spinal cord culture and subjected to live imaging

analysis. Live imaging was performed as described in whole mount samples, comparing samples treated with EV-calcein loaded and EV not loaded with calcein.

2.23 | Statistical Analyses

All data were processed, and statistical significance was determined using GraphPad Prism software version 10.0.0 for macOS (GraphPad Software, Boston, Massachusetts, USA). Data are presented as mean \pm standard error of the mean (SEM), standard deviation (SD) or median as specified. For all experiments, equal variance was assumed unless otherwise noted. Normality and lognormality were assessed using the Shapiro–Wilk test. For comparisons between two groups, Student’s t-test was applied to normally distributed data, while the Mann–Whitney U test was used for nonparametric data. For comparisons involving more than two groups, one-way ANOVA was applied to normally distributed data, followed by post hoc testing (Tukey’s test correction), whereas the Kruskal–Wallis test was used for nonparametric data, followed by Dunn’s post hoc test where applicable. Statistical significance was indicated as follows: $p > 0.05$ (ns), $p < 0.05$ (*), $p < 0.01$ (**), $p < 0.005$ (***) and $p < 0.0001$ (****).

3 | Results

3.1 | EV Administration Protects hMPCs and Improves the Myogenic Potential After Acute Damage in Standard Culture Conditions

Before generating a 3D muscle construct containing myogenic cells and macrophages, we established and analysed a 2D co-culture platform to test the different experimental conditions of interest (Figure 1A) and characterised the properties of EVs. At first, EV characterisation confirmed a double lipid bilayer in the nanoparticles with CryoTEM, their size and the presence of surface markers that characterised the EVs from MSCs, such as CD9, CD63 and CD81 (Figure S1). EVs do not express human




FIGURE 1 | hMPC and macrophages (M0) 2D co-culture setting of the damage and the rescue. (A) Model setup of hMPC and macrophages M0 co-culture and treatments: hMPC and macrophages M0 (negative control); hMPC and macrophages M0 with CTX damaged (positive control); hMPC and macrophages M0 with CTX damaged and EVs treatment; (B) Representative immunofluorescence images of damaged hMPC with CTX treated with EVs. Myosin (MHC) (in red) staining of the myofibres and DAPI (in blue) staining of the nuclei, an increase in myogenic index was noticed after EVs treatment (scale bar = 50 μ m). (C) Visualisation of co-culture of damaged hMPC and macrophages with CTX treated with EVs. Myosin (MHC) (in red) staining the myofibres, CD68 (in green) staining macrophages, and DAPI (in blue) staining the nuclei (scale bar = 50 μ m). (D) In the myogenic index comparison between hMPC culture and co-culture with macrophages (M0), an increase in the myogenic index was noticed in co-culture samples. (E) Graph representing the delta difference (Δ) between the myogenic index of hMPC culture and co-culture with macrophages in each proposed condition; an increase in the myogenic index was noticed in co-culture samples. Statistical analyses: ** $p < 0.01$ and **** $p < 0.0001$.

leukocyte antigen gene complex (HLA-II), underlining their property of immunomodulation.

Subsequently, we investigated whether EVs could sustain the hMPC myogenic potential upon different concentrations of CTX-induced damage. To accomplish this, we compared the myogenic fusion index of the hMPCs when cultured alone and co-cultured with macrophages before and after CTX damage, without and with EVs supplementation. We observed that, regardless the presence of macrophages, EVs enhanced the myogenic potential of hMPCs, as indicated by the myogenic fusion index (Figure 1B,C).

Specifically, we found that the fusion index significantly diminished after inducing CTX damage, with a reduction from $49.57\% \pm 8.73$ to $38.83\% \pm 5.30$ ($p = 0.0155$) in the hMPC culture and from $79.18\% \pm 7.18$ to $54.89\% \pm 20$ in the co-culture ($p \leq 0.0001$) (Figure 1B,C). When treated with EVs after CTX damage, samples with hMPCs ($38.83\% \pm 5.30$ to $58.18\% \pm 4.87$ $p \leq 0.0001$) and with hMPCs and macrophages co-culture ($54.89\% \pm 20.00$ to $80.50\% \pm 10.31$ $p \leq 0.0001$), were able to increase the myogenic fusion index comparable to the one observed in the CTX-damaged (Figure 1B,C). These results suggested the ability of the EVs to consistently protect the myotubes from acute

damage with CTX, improving their myogenic potential. We also tested different concentrations of the TNF α inhibitor (SPAD304) on CTX-damaged cells, in parallel with a pan-caspase inhibitor (Q-VD-OPh) (Figure S2). We focused on TNF α inhibitor because the results were more consistent.

Furthermore, the inclusion of macrophages in co-culture with hMPCs resulted in a significantly higher myogenic index compared to hMPCs cultured independently ($49.57\% \pm 8.73$ vs. $79.18\% \pm 7.18$, $p < 0.0001$), reflecting an increase of 29.6%. This effect was observed under both CTX treatment ($38.83\% \pm 5.3$ vs. $59.62\% \pm 20.42$, $p = 0.0074$) with a 16% increase and in the presence of EVs ($58.18\% \pm 4.87$ vs. $80.50\% \pm 10.31$, $p < 0.0001$) with a 22.3% increase (Figure 1D,E). These findings align with earlier reports (Juhas et al. 2018), reinforcing the role of macrophages in promoting hMPC differentiation and maturation under our co-culture conditions.

3.2 | Human Decellularised Muscle Can Generate a Functional Tri-Dimensional Muscle Model Engineered With hMPC and Macrophages

This study's decellularisation process was optimised explicitly for human muscle tissue. While our previous work demonstrated the use of the detergent SDC for decellularising murine muscle tissue (Magarotto et al. 2021), the findings of this study suggest that this protocol may not be as effective for human muscle. Here, we settled a decellularisation protocol based on LB, an inhibitor of actin polymerisation, which has already been used to produce decellularised murine muscles (Urciuolo et al. 2018). Efficient decellularisation was achieved through the combined action of the toxin and the DNase enzyme (Figure 2A and Figure S3). The reduction in DNA content was analysed after each decellularisation cycle using SDC and LB. A significant reduction in DNA content was observed only after three cycles of SDC ($p = 0.0125$) (Figure 2B). Additionally, the efficiency of LB in reducing DNA content was evaluated at different concentrations (50 and 500 nM). The results indicate that LB at 500 nM effectively removed DNA content after two cycles ($p = 0.0125$) (Figure 2C).

The LB decellularisation method demonstrated better preservation of key proteins, such as laminin ($p > 0.9999$) and collagen ($p = 0.0780$), with no significant differences observed when compared to the control group, apart from glycosaminoglycans that have a significant reduction ($p = 0.0343$) (Figure 2D). The scaffold's structural integrity was also maintained, resulting in a high-quality muscle scaffold. In contrast, samples treated with SDC showed a significant decrease in laminin ($p = 0.0056$) as well as glycosaminoglycans ($p = 0.0055$) and collagen ($p = 0.0197$) when compared to the control group, highlighting potential limitations for human muscle decellularisation (Figure 2D). Notably, neither decellularisation method adversely affected the mechanical properties of the treated tissues compared to the control (Figure 2E). Based on these results, we conducted the experiments decellularising ECMs using LB 500 nM for two cycles.

Our already set method for cell seeding in decellularised muscle was applied (Magarotto et al. 2021) (Figure 3A). Four days after cell injection, a homogeneous nuclei distribution (nuclei/100

μm^2) was observed in recellularised ECMs seeded with hMPCs, with no significant difference between cultures maintained in proliferative or differentiation medium ($p = 0.4375$) (Figure 3B).

Additionally, the homogeneous nuclei distribution (nuclei/100 μm^2) was evaluated in recellularised ECMs seeded with hMPCs and macrophages (Figure 3C). We demonstrated a distribution comparable to fresh muscle tissue, with no significant statistical differences between the fresh group and the recellularised ECM with hMPCs and macrophages ($p = 0.0079$). However, nuclei distribution seemed different in ECM recellularised just with hMPCs, which shows a significant difference compared to the fresh group ($p = 0.1134$). No significant differences were observed in the mechanical properties (stiffness, hardness and consistency) before and after seeding with hMPCs and macrophages (Figure 3D). We also confirmed that myotubes expressing the embryonic myosin heavy chain were present after 13 days of hMPCs and macrophage repopulation (Figure 3E). Notably, the tridimensionality construct possessed functional activity, as shown by the electrical stimulation of the construct and force generation (Figure 3F,G). The construct responded to electrical stimulation at increasing frequency, showing an increase in tension produced and an increase in contraction velocity. In fact, the steepness of the tension signal at the beginning of the electrical stimulation increases progressively with the stimulation frequency. After stimulation, the construct showed some relaxation traits that are possibly dampened by the heterogeneity of the matrix stiffness, as well as by an unrefined calcium uptake machinery.

3.3 | EVs Protect Human Muscle Construct From Damage, and This Effect Can Be Mimicked by Inhibiting the TNF α

Once we confirmed that our experimental strategy could generate a functional 3D-engineered human skeletal muscle model, we further evaluated the ability of EVs to protect myogenic cells from damage. We followed the experimental approach for bidimensional cell cultures described above (Figure 4A), comparing CTX-treated muscle constructs with untreated samples or damaged samples supplemented with EVs or TNF α inhibitor. Initially, we confirmed that functional muscle constructs expressed myogenic proteins, including actin, embryonic myosin heavy chain (eMHC) and myogenin (Figure 4B), without damage. Upon CTX damage and without EV administration, muscle constructs exhibited a reduced presence of myogenic components (Figure 4B). Furthermore, macrophage M0 infusion into the ECMs showed a significant upregulation of MCP1 gene expression in response to CTX damage without EV administration ($p = 0.0421$). This upregulation was significantly reduced in damaged samples treated with EVs ($p = 0.0236$) or TNF α inhibitor ($p = 0.0478$) compared to damaged recellularised ECMs. In contrast, ARG1 expression was significantly downregulated in the CTX-damaged samples without EV administration ($p = 0.0450$), while a significant upregulation was observed in the damaged samples treated with EVs ($p = 0.0300$) or TNF α inhibitor ($p = 0.0444$) (Figure 4C).

A trend towards an increase in the number of cleaved caspase 3 (cCAS3)⁺ apoptotic cells ($p = 0.0551$) and a decrease in the




FIGURE 2 | Comparison of different decellularisation protocols of human muscle biopsy. (A) Decellularisation process of human muscle samples with SDC following three cycles and LB protocols following two cycles. (B) DNA content variation (fold change) in tissue samples decellularised using SDC protocol. (C) DNA content variation (fold change) in tissue samples decellularised using LB protocol. (D) Representative images of human muscle tissue were decellularised using SDC and LB protocols and stained with fibronectin (red) and laminin (green), Alcian blue (blue) and collagen (SHG). The graphs show Mean Fluorescence Intensity (MFI) of LAM, glycosaminoglycan (GAG) content and Second Harmonic Generation (SHG) coherency. (E) Mechanical properties of decellularised human muscle tissue, including stiffness, hardness and consistency. Data are represented as mean \pm standard deviation. No significant differences were observed across protocols for these parameters. * $p < 0.05$; ** $p < 0.01$; 'ns' denotes no significance.

number of proliferating Ki67⁺ cells ($p = 0.5718$) was observed in CTX-damaged samples without EV administration when compared to controls (Figure 4D). Conversely, when EVs were administered to CTX-damaged muscle constructs, the number of cCAS3⁺ apoptotic cells ($p = 0.9400$) and proliferating Ki67⁺ cells ($p = 0.1738$) was similar to that seen in undamaged samples (Figure 4D).

Additionally, a significant decrease in the number of cCAS3⁺ cells was observed in samples treated with EVs ($p = 0.0008$) and TNF α inhibitor ($p = 0.0010$), along with an increase in Ki67⁺ cells in the EV-treated samples ($p = 0.0050$) (Figure 4D).

These data confirmed that EVs protect myotube integrity and myogenic survival upon acute damage *in vitro*. Interestingly, a




FIGURE 3 | Decellularised ECM engineered with hMPC and macrophages. (A) Experimental design: decellularisation and recellularisation of ECMs with hMPC and macrophages M0. (B) Whole mount staining of ECM recellularised with hMPC: Evaluation of nuclei and ki67 positive cells in ECM recellularised with hMPC under proliferative and differentiation medium conditions. Nuclei staining (in blue) (scale bar = 100 and 50 μm). (C) Immunostaining of ECM recellularised with hMPC and macrophages (M0): Myosin staining (in red) and nuclei staining (in blue). Comparison of nuclei/mm² percentage in native muscle tissue, ECM recellularised with hMPC with proliferative and differentiation medium. (D) Stiffness, Hardness, and Consistency comparison between muscle native tissue and ECM recellularised with hMPC and M0. (E) Whole mount of ECM recellularised with hMPC and macrophages (M0). The presence of new fibres marked with embryonic myosin heavy chain (eMHC) can be seen in green, and the phalloidin in red (scale bar = 50 μm). (F) Tension-resistant experiment of ECM recellularised with hMPC and macrophages: Measurement of ECM tension resistance. (G) The graph results from tension-resistant experiments in ECM control and cardiotoxin damage. Control = Recellularised ECM with hMPCs and macrophages; Cardiotoxin = Damaged recellularised ECM with hMPCs and macrophages. g = gram ***p* < 0.01; 'ns' denotes no significance.




FIGURE 4 | Characterisation of cardiotoxin (CTX) damaged recellularised extracellular matrix (ECM) with human muscle precursor cells (hMPC) and macrophages MO treated with Extracellular Vesicles (EVs). (A) Experimental design: decellularisation and recellularisation of ECMs with hMPC and macrophages MO followed by CTX damage and EVs treatment. (B) Comparison between recellularised ECM with hMPC and macrophages MO – (Control) and recellularised ECM with hMPC and macrophages MO damaged with CTX – (+CTX). Nuclei (in blue), α Actin (in red), embryonic myosin heavy chain (eMHC) (in red), Laminin (in green), CD68 (in blue), Myogenin (MyoG) (in red). (scale bar = 50 μ m). (C) Comparison of the MCP1 and ARG1 genes expression among recellularised ECM with hMPC and macrophages MO – (Control), recellularised ECM with hMPC and macrophages MO damaged with CTX – (+CTX), +CTX treated with EVs, and +CTX treated with TNF α inhibitor. (D) Viability analysis evaluating the expression of α CAS3 and Ki67 by immunofluorescence into recellularised ECM with hMPC and macrophages MO – (Control) and recellularised ECM with hMPC and macrophages MO damaged with CTX – (+CTX), +CTX treated with EVs, and +CTX treated with TNF α inhibitor. Statistical analyses: * p < 0.05; ** p < 0.01; *** p < 0.001.

similar result was observed with TNF α inhibitor administration after damage. EVs showed inhibition of TNF α , counteracting apoptosis in CTX+EVs and CTX+ TNF α inhibitor samples and improving cell proliferation (Figure 4). These findings lay the foundation for the investigation of the mechanism of action of EVs towards muscle regeneration. Initially, we observed that MO macrophages exhibited a phenotype characteristic of M1-polarised macrophages, as indicated by NOS2 expression, which is associated with pro-inflammatory activity. Conversely, our results demonstrate that treatment with EVs or TNF α inhibitor promoted the polarisation of M2 macrophages, as indicated by ARG1 expression, which is associated with anti-inflammatory functions and tissue repair. Additionally, we showed that EVs influence cell proliferation while concomitantly inhibiting apoptosis.

3.4 | EVs Modulate Apoptosis and Inflammation, Stimulating Muscle Regeneration

Once our 3D *in vitro* model possesses both myogenic cells and macrophages, we decided to investigate further the EVs

action effect and how it could be linked to the inflammatory response state of the culture. We demonstrated that EVs are rich in miRNA involved in inflammation and tissue regeneration (Figure 5A).

We analysed the expression of specific miRNAs, genes, and proteins involved in inflammation and muscle regeneration. The miRNA analysis revealed that miR-145-5p, a miRNA strongly associated with the upregulation of the pro-inflammatory gene TNF α (Tahamtan et al. 2018), was significantly upregulated in CTX-damaged samples without any treatment compared to controls (p = 0.0019). However, its expression was significantly downregulated following treatment with EVs (p = 0.0173) or TNF α inhibitor (p = 0.0019) (Figure 5B). A similar regulatory pattern was observed for miR-21-5p, which was upregulated in CTX-damaged samples without treatment compared to controls (p = 0.0305) and significantly downregulated following EVs (p = 0.0357) or TNF α inhibitor (p = 0.0358) treatment (Figure 5B). Interestingly, miR-206-5p showed significantly higher expression in samples treated with EVs than controls (p = 0.0428) and TNF α inhibitor-treated samples (p = 0.0081).




FIGURE 5 | microRNA, mRNA, and cytokine expression. (A) Heatmap of the most expressed microRNAs carried by extracellular vesicles ($n = 5$). (B) Comparison of microRNAs expression (miR-145-5p, miR-21-5p and miR-206-5p), following recellularisation of ECMs with hMPC and macrophages M0, followed by CTX damage, EVs treatment, TNF α inhibitor and miR-145-5p inhibitor. (C) mRNA gene expression, including TNF α and muscle regeneration-related genes (NOTCH1 and MyoD), after recellularisation of ECMs with hMPC and macrophages M0, followed by CTX damage, EVs treatment, TNF α inhibitor and miR-145-5p inhibitor. (D) Cytokine array expression, including TNF α , RANTES and IL10 (an inflammatory suppressor), after recellularisation of ECMs with hMPC and macrophages M0, followed by CTX damage, EVs treatment and TNF α inhibitor. Statistical analyses: * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$; **** $p < 0.0001$.

Remarkably, the *TNF α* gene expression was detected in the damaged samples without any treatments (Figure 5C), being significantly upregulated when compared to control ($p = 0.0012$) and EVs ($p = 0.0028$) treatment. Indeed, it was also confirmed by TNF α protein analysis, where the CTX-damaged samples without any treatment showed a higher protein level expression when compared with control ($p = 0.0007$), EVs ($p = 0.0037$) and TNF α inhibitor ($p = 0.0055$) treatment (Figure 5D). Interestingly, the addition of anti-miRNA145-5p in the CTX group led to increased *TNF α* expression, similar to the CTX-treated group (Figure 5C). Additional analysis also underlined the downregulation of the TNF receptor-associated factor 2 (*TRAF2*) gene in samples treated with EVs after CTX damage ($p = 0.00446$) (Figure S4). No significant results were attained with the Nuclear Factor kappa-

light-chain-enhancer of activated B cells (*NF-kB*) gene that regulate inflammation (Figure S4).

These results strongly suggest that EVs may regulate apoptotic pathways and fibrosis and promote myoblast differentiation. It proposes the anti-inflammatory role of EVs through the reduction of *TNF α* expression.

Regarding the cell development and myogenic differentiation states, no significant difference in *NOTCH1* expression was observed (Figure 5C). However, *MYOD* expression was upregulated in EV-treated samples ($p = 0.0222$) compared to CTX-damaged samples without treatment. Notably, a difference between EV-treated samples and TNF α inhibitor was significant

($p = 0.0107$), suggesting that TNF α inhibitor is not able to stimulate muscle cell differentiation after CTX damage (Figure 5C). In the CTX and CTX anti miRNA145-5p groups the *MYOD* and *NOTCH1* genes were similarly expressed (data not shown).

The expression of anti-inflammatory cytokines was also evaluated. The cytokine Regulated on Activation Normal T-cell Expressed and Secreted (RANTES) was significantly overexpressed on samples damaged with CTX treated with EVs ($p = 0.0495$) and TNF α inhibitor ($p = 0.0001$). Similar results were observed in the Interleukin-10 (IL10) analysis, which was significantly under-expressed in CTX-damaged samples without treatment compared to controls ($p = 0.0002$). Conversely, IL10 was significantly overexpressed in all treated conditions: EVs ($p = 0.0027$) and TNF α inhibitor ($p = 0.0001$) (Figure 5D). These findings underline the role of the nanoparticles as modulators of apoptosis and inflammation in favour of a pro-regenerative response.

3.5 | EVs Strongly Inhibit Neuroinflammation by Reducing TNF α in Microglia Cells

To validate that EVs are able to modulate neuroinflammation via TNF α regulation, we investigated their effects of EVs on primary microglia cells *in vitro* by evaluating TNF α levels in the supernatant (Figure 6A). Phase contrast images reveal that cells continue attached after LPS stimulus and after EV treatments (Figure 6B). Therefore, samples stimulated with LPS and treated with the low ($p = 0.0330$) and highest dose of EVs ($p = 0.0331$) showed increased viability when compared with LPS-stimulated control (Figure 6C). Regarding TNF α quantification, microglia stimulated with LPS exhibited a significantly higher TNF α release compared to the unstimulated group ($p \leq 0.0001$), confirming the efficiency of LPS in inducing an inflammatory response in microglia (Figure 6D). Notably, EVs at their maximum dose (3×10^9) significantly inhibited TNF α levels compared with the LPS-stimulated control ($p \leq 0.0001$). These findings suggest that EVs exert their anti-inflammatory effects by reducing TNF α levels, reinforcing their potential role as modulators of neuroinflammation.

3.6 | Neural Axon Sprouting Is Stimulated in the Organotypic Culture of Embryonic Rat Spinal 3D *In Vitro* Model by EVs by Activating the TNF α

Based on the results obtained so far, we further investigated the mechanism of action of EVs that could also be relevant to the neural compartment. We used a 3D organotypic culture of embryonic rat spinal cord (oSpCs) to accomplish this (Raffa et al. 2020). Thus, spinal cords isolated from rat embryos were sectioned into three segments allocated within Matrigel droplets to obtain oSpC 3D cultures (Figure 7A). At first, we confirmed that calcein-embedded EVs were uptake by the oSpCs in 48 h (Figure 7B). Then, we compared organotypic culture behaviour in the absence or presence of EVs. Interestingly, 48 h after culture, the sprouting of neural axon projections was improved in oSpC treated with EVs compared with the untreated time-matched samples (Figure 7C). We found that EVs administration increased neuronal projection length (291.55 ± 13.87) when compared to

untreated samples after 48 h in culture (238.90 ± 26.93) ($p = 0.0040$) (Figure 7D). Moreover, after 48 h in culture, the number of axons (113 ± 73) also significantly increased during culture in oSpCs treated with EVs when compared to the untreated samples (38 ± 32) ($p = 0.0030$) (Figure 7E). Additionally, oSpC samples treated with miR-145-5p inhibitor showed shorter axon projections compared to those treated with miR-145-5p inhibitor and EVs after 24 h (100.82 ± 39.07 vs. 291.55 ± 13.87 , $p < 0.0001$) and 48 h (120.81 ± 49.25 vs. 291.55 ± 13.87 , $p < 0.0001$; Figure 5S). On one hand, the axon projection length was not statistically different in samples treated with miR-145-5p inhibitor followed by EVs treatment at 48 h compared to those treated with EVs alone after 48 h (242.62 ± 86.84 vs. 290.02 ± 108 , $p = 0.1834$) (Figure 5S). On the other hand, after 48 h, samples treated with miR-145-5p inhibitor displayed significant downregulation of miR-145-5p ($p = 0.0001$) and upregulation of TNF α gene (Figure 7F,G), confirming the relation between EV action in TNF α pathway via miR-145-5p.

Moreover, the functionality of the neurons did not appear modified by the EV administration, as shown by calcium transient live imaging analysis of Fluo-4-stained samples (Figure S6 and Video S1). In addition, neuronal cells supporting glial cells were preserved after EV administration (Figure S7).

We further investigated key players involved in neural inflammation to understand whether EVs could regulate inflammation and act through TNF α in the neural compartment. We observed that, when oSpCs were treated with EVs, miR145-5p decreased ($p = 0.0041$), as well as the gene ($p = 0.0012$) and the protein ($p = 0.0260$) expression of TNF α (Figure 7F,G). Proteins linked to neural inflammation and cell growth, the tissue inhibitor of metalloproteases-1 (TIMP-1) ($p = 0.0032$) and the Intercellular Adhesion Molecule 1 (ICAM-1), were significantly ($p = 0.0066$) overexpressed in samples treated with EVs (Figure 7H), indicating that EVs modulate inflammation during axonal sprouting in oSpC model. These data are in accordance with those obtained from the skeletal muscle 3D model, strongly suggesting that EVs have a common modulatory effect on TNF α via miR145-5p.

4 | Discussion

In this work, we investigated the mechanism of action of EVs towards muscle regeneration using *ex-vivo* models that mimic the multifaceted tissue of the muscle and the neural tissue. We considered the complexity of the environment in terms of both the cellular and protein aspects.

Firstly, we demonstrated that decellularised ECM derived from healthy human muscle biopsies, engineered with hMPCs and macrophages, closely resembles the native muscle tissue environment. The decellularisation method is critical for obtaining a functional ECM that retains essential components such as collagens, glycoproteins, and proteoglycans while preserving its intricate architecture to support successful tissue engineering applications (Hong et al. 2018). Our group previously demonstrated the efficient decellularisation of mouse ECM using SDC (Magarotto et al. 2021). However, our first attempt to replicate the same protocol already used in mice in human muscle was inefficient due to the lack of protein structure preservation and the preservation of DNA content. Other studies suggest




FIGURE 6 | TNF α reduction in microglia cells after naïve EVs treatment. (A) Experimental design: BALB/C microglia cells isolation, expansion and stimulation with LPS, and treatment with naïve EVs and prednisolone. (B) Representative images of microglia morphology. Phase contrast images represent the cells stimulated with LPS only and cells treated with EVs (maximal dose 3×10^9 /well) in the presence of LPS (Scale bar = 150 μ m). (C) Viability test performed of the following experimental groups: (1) non-treated cells; (2) cells stimulated with LPS only; (3) cells treated with prednisolone (positive inhibition control) in the presence of LPS; (4) cells treated with naïve EVs (3×10^8 /well; 8×10^8 /well; 3×10^9 /well) in the presence of LPS. (D) Quantification of TNF α cytokine (pg/mL) released into supernatants of the following experimental groups: (1) non-treated cells; (2) cells stimulated with LPS only; (3) cells treated with prednisolone (positive inhibition control) in the presence of LPS; (4) cells treated with naïve EVs (3×10^8 /well; 8×10^8 /well; 3×10^9 /well) in the presence of LPS. Statistical analyses: * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$; **** $p < 0.0001$.

Latrunculin B may offer structural advantages as a decellularising agent (Urciuolo et al. 2018). The toxin enables rapid and specific cell detachment by removing cellular DNA, inhibiting actin polymerisation, and actively inducing protein disassembly while minimising ECM disruption (Urciuolo et al. 2018; Assmann et al. 2017; Reyna et al. 2020). In this study, we compared the efficiency of SDC and Latrunculin B in decellularising human muscle biopsies. Notably, Latrunculin B proved to be faster, requiring only two cycles to completely remove all DNA while significantly preserving the integrity of laminins and collagen and maintaining mechanical properties.

Efficient decellularisation considerably impacts the recellularisation process (García-García et al. 2023). The cell reseeding of decellularised skeletal muscle ECMs has been previously described (Magarotto et al. 2021; Juhas et al. 2014; Trevisan et al. 2019) along with the micro-injection of hMPCs capable of proliferating, differentiating, and forming myotubes. In the present study, M0 macrophages were co-injected with hMPCs, further enhancing the ability to mimic the *in vivo* environment. Based on our results, using Latrunculin B for decellularising human skeletal muscle allowed the maintenance of ECM biological structure, enabling the reseeding, proliferation and differentiation of hMPCs and macrophages.

Developing a 3D model based on human ECM decellularised tissue that is also attractive for cell culture could be a promising platform strategy to mimic the microenvironment and even recreate a pathologic microenvironment. The present model aimed to recapitulate the skeletal muscle loss that can happen after an accident, surgery resection, and congenital malformation in newborns.

Indeed, CTX was used to model skeletal muscle damage, and recovery was observed following treatment with EVs. Other researchers have reported that CTX damages myofibres by acting on calcium ion-binding sites, disrupting calcium release from the sarcoplasmic reticulum and triggering an inflammatory response (Lin Shiao et al. 1976; Fletcher et al. 1991; Wang et al. 2022).

The co-seeding of hMPC and macrophages appeared essential for stimulating muscle cell fusion (Tidball and Villalta 2010; Sicari et al. 2014). In particular, macrophages are crucial for hMPCs recovery after inflammatory damage, supporting and stimulating the cells to proliferate parallel, decreasing cell death (Wang et al. 2022; Tidball and Villalta 2010; Goto et al. 2021). On this ground, our group showed *in vitro* the use of EVs in muscle regeneration after CTX injury (Magarotto et al. 2021), and *in vivo* after muscle loss, highlighting their anti-inflammatory effects, promotion of




FIGURE 7 | Spinal cord regeneration. (A) Experimental design: rat spinal cord isolation, sectioning and culture in Matrigel domes followed by EVs treatments and analyses after 48 h. (B) Calcein (green) uptake comparison analysis on untreated spinal cord and EVs treated after 48 h. (Scale bar: 500 μm) (C) Immunofluorescence images of axonal sprouting stained with TUJ-1 (green) and nuclei (blue) on untreated spinal cord or EVs treated oSpC after 48 h. (Scale bar = 50 μm). (D) Quantification of axonal projections length in untreated samples (UNTR) or EVs treated oSpC cultured for 24 or 48 hours. A.U: arbitrarily unit. (E) Quantification of axonal projections number in UNTR samples or EVs oSpC cultured for 48 hours. (F) Quantification of microRNA (miR-145-5p) expression in UNTR oSpC or in samples treated with EVs or miR-145-5p inhibitor cultured for 48 h. (G) Quantification of mRNA (Tnf α and Neurofilament) expression in UNTR samples, or in oSpC treated with EVs or miR-145-5p inhibitor samples cultured for 48 hours. (H) Cytokine array expression, including TIMP-1, ICAM-1 and TNF α in UNTR samples and EV treated cultured for 48 hours; Statistical analyses: ns: not significant. * $p < 0.05$; ** $p < 0.01$; **** $p < 0.0001$.

angiogenesis and facilitation of muscle recovery (Magarotto et al. 2021; Mitchell et al. 2019; Balbi et al. 2017). In addition, we have already demonstrated that the dose of 1×10^9 EVs is efficient when tested *in vitro* using the potency assay Griess that evaluate the anti-inflammatory properties (Malvicini et al. 2022; Zaramella et al. 2025).

These results were reinforced using a complex environment to mimic the crosstalk between the cells and ECM, combining different cell types. The mechanical properties of decellularised muscle ECM, when compared with the native tissue, were not significantly different, suggesting that the tissue maintained the native characteristics. In addition, the physiologic assay reveals the basal electrical activity in recellularised muscle ECM (hMPCs and macrophages) that was lost after CTX damage. Using our model, we suggest the strong correlation of anti-inflammatory effects of EVs through the inhibition of TNF α by regulation of microRNAs expression.

MicroRNAs in muscles have already been described as a key factor for muscle regeneration after damage (Aránega et al. 2021). MicroRNAs are constantly related to promoting or regulating

diseases, like the miR-145-5p associated with skeletal muscle dysfunction, inducing apoptotic cell death and curbing cell proliferation through inactivating (Jin et al. 2022). The miR-21 is a highly upregulated microRNA associated with muscle cells during tissue injury, which regulates ECM remodelling and promotes fibrosis (Ardite et al. 2012; Zanotti et al. 2015). Furthermore, miR-206-5p has been associated with one of the most important microRNAs during skeletal muscle myogenesis, promoting myogenic progenitor cell proliferation (Aránega et al. 2021). In addition, miR206-5p also enhances myoblast differentiation by targeting important inhibitors of myogenesis (Liu et al. 2012; Dey et al. 2011). In our study, microRNA expression of miR-145-5p, miR-21-5p and miR-206-5p showed upregulated on the damaged samples. Although there was a tendency to downregulate after EVs treatment, these results were similar when compared to TNF α inhibitor-treated samples and control.

EVs from MSCs are endogenously loaded with a heterogeneous population of microRNAs, including miR-3196, miR-125b-5p, among others (Mellows et al. 2017). In our study, we demonstrated that GMP-grade EVs are loaded with miR-145-5p and miR-21-5p, as shown by miRNOME. Based on our findings and from

other researchers (Mellows et al. 2017), we hypothesise that this heterogeneous expression profile synergistically supports muscle recovery.

Importantly, the functional inhibition of miR-145-5p, both *ex vivo* 3D model and *in vitro*, confirmed its mechanistic role in regulating inflammatory and regenerative pathways. Specifically, suppression of miR-145-5p led to increased TNF- α by TRAF2, consistent with its known function as a negative regulator of NF- κ B signalling (Cho et al. 2021; Zhang et al. 2022; Jin et al. 2022). These findings demonstrate a functionally causal relationship between miR-145-5p modulation and the anti-inflammatory effects induced by EV treatment.

Our observations align with previous studies showing that miR-145-5p influences muscle cell proliferation, differentiation, and inflammation through the Wnt signalling pathway (Shin et al. 2024). These results support the idea that the miRNA content of EVs plays a complex role in muscle regeneration by reducing inflammation signals and enhancing myotube development. Our data offer functional proof that miR-145-5p is a crucial factor in the regenerative and anti-inflammatory actions of GMP-grade EVs, building on previous correlative studies and emphasising the therapeutic potential of EV-associated microRNAs in skeletal muscle regeneration.

In our study, we demonstrated that the action of macrophages in rescuing damaged muscle cells through the secretion of paracrine factors, without any additional stimulus, is insufficient to fully recover cells from CTX-induced damage, as they exhibit a pro-inflammatory (MCP1+) profile. However, after treatment with EVs, an upregulation of the anti-inflammatory marker ARG1+ is observed (Juhás et al. 2018). This effect is further supported by reducing TNF α expression at both the gene and protein levels following EV treatment. These results highlight the sustained benefits of anti-inflammatory effects promoted by EVs in modulating inflammation and enhancing tissue repair by upregulating MyoD expression.

Notably, the anti-inflammatory action of EVs following CTX treatment was highlighted by the enhanced expression of the chemokine RANTES and the cytokine IL-10. RANTES is recognised as a key modulator of the immune response in muscle and serves as a chemotactic factor for myoblast (Kohno et al. 2011; Demoule et al. 2005). Furthermore, to sustain the anti-inflammatory regulation observed after EV treatment, we demonstrated the upregulation of IL-10, a well-known anti-inflammatory cytokine and a direct regulator of muscle repair during inflammation (Juhás et al. 2018; Deng et al. 2012), in CTX-damaged samples treated with EVs. These findings support the role of EVs in reducing inflammation and promoting muscle repair.

To confirm the anti-inflammatory potential of EVs in a neural environment, we tested them on microglial cells. They are the primary innate immune cells of the neural system and serve as key mediators of neuroinflammatory processes (Biswas 2023), once the microglia and macrophages behave as a single cellular population (Cuadros et al. 2022). The use of LPS to induce inflammation in the murine BV-2 microglial cell line is a widely accepted *in vitro* model of neuroinflammation (Zong et al. 2021; Markoutsas

et al. 2022). However, to complement the results obtained in the muscle model, we induced neuroinflammation in a primary murine microglial cell culture stimulated with LPS. The results of the GMP-grade EVs in our *in vitro* microglial model also aligned with those observed in our 3D model of recellularised ECM containing hMPCs and macrophages, confirming the regulation of TNF α by EVs.

Previous studies demonstrated that EV treatments promote not only skeletal muscle regeneration but also have a significant impact on nerve-mediated functionality of the skeletal muscle (Muir et al., 2002; Yang et al., 2011). In our spinal cord model, the inflammatory TNF α , gene and protein were downregulated in samples after EV treatment. This modulation of the inflammation stimulates TIMP-1 towards astrocyte recovery (Muir et al. 2002) and increases the expression of ICAM-1 protein implicated in inflammation and cell recruitment (Yang et al. 2011).

Our study provides strong evidence supporting the anti-inflammatory and regenerative potential of GMP-grade MSC-derived EVs in 3D recellularised muscle constructs. While these findings represent an important step towards clinical translation, further studies are warranted to deepen understanding of the physiological variables that may influence EV activity (Keshtkar et al. 2018). The 3D culture system used here offers a reproducible and physiologically relevant platform, though future scale-up using bioreactor technologies could enhance its translational applicability (Guller and Igrunkova 2023). Additionally, as EV-based therapies progress towards clinical use, continued efforts to standardise dosing and ensure manufacturing consistency will be critical (Nelson et al. 2025). Overall, our work lays a strong foundation for advancing GMP-compliant EVs as promising candidates for muscle regeneration therapies.

To conclude, we aimed to create a biomimetic system where the physical interactions among the muscle, the neural, the immunological cells and ECM were replicated.

At first, for the muscle model, we were able to set an efficient decellularisation method that preserves mechanical properties and protein content. It is already known that to understand the *in vivo* complex phenomena such as biological processes and their mechanism of action, recent advances in tissue-engineered organs-on-chips have enabled three-dimensional cell modelling (Bhatia and Ingber 2014; Clevers 2016). We recapitulated three-dimensional engineered muscle tissues that modelled muscle cells' quiescence, self-renewal and response to injury (Juhás et al. 2014). Similarly, the neural model was responsive to EVs and allowed the detection of tissue regeneration. Through these tissue-mimetic tools, we documented one, among others, the mechanism of action of EVs through the TNF α modulation via miRNA. These natural, non-toxic nanoparticles act in both muscle and neural compartments, modulating the microenvironment through their content, and can represent a new therapeutic tool for skeletal muscle disorders.

Author Contributions

Agner Henrique Dorigo Hochuli: methodology, writing – original draft, data curation, conceptualisation, formal analysis. **Stefania**

D'agostino: methodology, data curation. **Lucia Rossi:** data curation. **Beatrice Auletta:** methodology, data curation. **Leonardo Nogara:** methodology, data curation. **Giovanni Tafuro:** methodology, data curation. **Giuseppe Germano:** methodology. **Alice Zaramella:** methodology, formal analysis. **Paola Bisaccia:** methodology, formal analysis. **Francesca Cecchinato:** methodology. **Carlo Biz:** methodology. **Gabrielis Kundrotas:** methodology, data curation, writing – review and editing. **Pietro Ruggieri:** methodology. **Alessandra Semenzato:** methodology. **Maurizio Muraca:** validation, visualisation. **Filippo Romanato:** methodology. **Piergiorgio Gamba:** methodology. **Marcin Jurga:** visualisation, validation, methodology. **Bert Blaauw:** methodology. **Anna Urciuolo:** validation, methodology, visualisation, writing – review and editing. **Michela Pozzobon:** conceptualisation, methodology, validation, writing – original draft, data curation, funding acquisition, formal analysis.

Acknowledgements

We want to thank Domenico Mancuso, Elisabetta Gramegna, Dimitri Stevens and Ruben Hermans from EXO Biologics for their assistance with producing and characterising EVs and Dr. Carmen López-Iglesias from the Faculty of Health, Medicine and Life Sciences in Maastricht, the Netherlands, for providing services in CryoTEM analysis.

Open access publishing facilitated by Università degli Studi di Padova, as part of the Wiley - CRUI-CARE agreement.

Funding

This work was supported by the Institute of Paediatric Research Città della Speranza, Padova, Italy, under Grant 21/07, P.I.: Michela Pozzobon and Grant number 21/05, P.I.: Anna Urciuolo; G.K. was supported by European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No. 797424 for microglia *in vitro* tests. This project was co-funded by EXO Biologics SA (Belgium) and supported by the DGO6 funding from the Wallonie Recherche SPW in Belgium (Grants No. 8358 and No. 8357).

Conflicts of Interest

We declare that M.J. is employed by EXO Biologics, while G.K. holds a consultancy position with the company. Furthermore, all other authors state that they have no known competing financial interests or personal relationships that could have influenced the work presented in this paper. The authors declare that a patent application related to the content of this manuscript has been filed.

Data Availability Statement

Raw data will be provided upon reasonable request to the corresponding author.

References

Aránega, A. E., E. Lozano-Velasco, L. Rodríguez-Outeiriño, F. Ramírez de Acuña, D. Franco, and F. Hernández-Torres. 2021. "MiRNAs and Muscle Regeneration: Therapeutic Targets in Duchenne Muscular Dystrophy." *International Journal of Molecular Sciences* 22: 4236. <https://doi.org/10.3390/ijms22084236>.

Ardite, E., E. Perdiguero, B. Vidal, S. Gutarra, A. L. Serrano, and P. Muñoz-Cánoves. 2012. "PAI-1-Regulated miR-21 Defines a Novel Age-Associated Fibrogenic Pathway in Muscular Dystrophy." *Journal of Cell Biology* 196: 163–175.

Assmann, A., M. Struß, F. Schiffer, et al. 2017. "Improvement of the In Vivo Cellular Repopulation of Decellularized Cardiovascular Tissues by a Detergent-Free, Non-Proteolytic, Actin-Disassembling Regimen." *Journal of Tissue Engineering and Regenerative Medicine* 11: 3530–3543.

Balbi, C., M. Piccoli, L. Barile, et al. 2017. "First Characterization of Human Amniotic Fluid Stem Cell Extracellular Vesicles as a Power-

ful Paracrine Tool Endowed With Regenerative Potential." *Stem Cells Translational Medicine* 6: 1340–1355.

Bhatia, S. N., and D. E. Ingber. 2014. "Microfluidic Organs-on-Chips." *Nature Biotechnology* 32: 760–772. <https://doi.org/10.1038/nbt.2989>.

Bisaccia, P., F. Magarotto, S. D'Agostino, et al. 2024. "Extracellular Vesicles From Mesenchymal Umbilical Cord Cells Exert Protection Against Oxidative Stress and Fibrosis in a Rat Model of Bronchopulmonary Dysplasia." *Stem Cells Translational Medicine* 13: 43–59.

Biswas, K. 2023. "Microglia Mediated Neuroinflammation in Neurodegenerative Diseases: A Review on the Cell Signaling Pathways Involved in Microglial Activation." *Journal of Neuroimmunology* 383: 578180. <https://doi.org/10.1016/j.jneuroim.2023.578180>.

Chan, B. P., and K. W. Leong. 2008. "Scaffolding in Tissue Engineering: General Approaches and Tissue-Specific Considerations." *European Spine Journal* 17: 467–479.

Chen, J.-F., Y. Tao, J. Li, et al. 2010. "microRNA-1 and microRNA-206 Regulate Skeletal Muscle Satellite Cell Proliferation and Differentiation by Repressing Pax7." *Journal of Cell Biology* 190: 867–879.

Chen, M., R. Jiang, N. Deng, X. Zhao, X. Li, and C. Guo. 2022. "Natural Polymer-Based Scaffolds for Soft Tissue Repair." *Frontiers in Bioengineering and Biotechnology* 10: 954699. <https://doi.org/10.3389/fbioe.2022.954699>.

Cho, K.-A., D.-W. Choi, Y.-H. Kim, J. Kim, K.-H. Ryu, and S.-Y. Woo. 2021. "Mesenchymal Stem Cell-Derived Exosomes Protect Muscle Loss by miR-145-5p Activity Targeting Activin A Receptors." *Cells* 10: 2169.

Clevers, H. 2016. "Modeling Development and Disease With Organoids." *Cell* 165: 1586–1597.

Collins, R. A., and M. D. Grounds. 2001. "The Role of Tumor Necrosis Factor-Alpha (TNF-) in Skeletal Muscle Regeneration: Studies in TNF(-) and TNF(-) LT(-) Mice." *Journal of Histochemistry & Cytochemistry* 49: 989–1001. <http://www.jhc.org>.

Cuadros, M. A., M. R. Sepulveda, D. Martin-Oliva, J. L. Marín-Teva, and V. E. Neubrand. 2022. "Microglia and Microglia-Like Cells: Similar But Different." *Frontiers in Cellular Neuroscience* 16: 816439. <https://doi.org/10.3389/fncel.2022.816439>.

Demoule, A., M. Divangahi, G. Danialou, et al. 2005. "Expression and Regulation of CC Class Chemokines in the Dystrophic (mdx) Diaphragm." *American Journal of Respiratory Cell and Molecular Biology* 33: 178–185.

Deng, B., M. Wehling-Henricks, S. A. Villalta, Y. Wang, and J. G. Tidball. 2012. "IL-10 Triggers Changes in Macrophage Phenotype That Promote Muscle Growth and Regeneration." *Journal of Immunology* 189: 3669–3680.

Dey, B. K., J. Gagan, and A. Dutta. 2011. "miR-206 and -486 Induce Myoblast Differentiation by Downregulating Pax7." *Molecular and Cellular Biology* 31: 203–214.

Filippi, A., E. Dal Sasso, and L. Iop. 2018. "Multimodal Label-Free Ex Vivo Imaging Using a Dual-Wavelength Microscope With Axial Chromatic Aberration Compensation." *Journal of Biomedical Optics* 23: 1–9.

Fletcher, J. E., M.-S. Jiang, Q.-H. Gong, M. L. Yudkowsky, and S. J. Wieland. 1991. "Effects of a Cardiotoxin From *Naja naja kaouthia* Venom on Skeletal Muscle: Involvement of Calcium-Induced Calcium Release, Sodium Ion Currents and Phospholipases A2 and C." *Toxicol* 29: 1489–1500.

Franzin, C., M. Piccoli, L. Urbani, et al. 2016. "Isolation and Expansion of Muscle Precursor Cells From Human Skeletal Muscle Biopsies." *Methods in Molecular Biology* 1516: 195–204. https://doi.org/10.1007/978-1-4939-9209-0_49-1.

García-García, Ó. D., J. Chato-Astrain, A. H. D. Hochuli, M. Pozzobon, and V. Carriel. 2023. "Decellularized Tissue-Derived Materials for Grafts Development." In *Handbook of the Extracellular Matrix*, 1–35. Springer International Publishing. https://doi.org/10.1007/978-3-030-92090-6_49-1.

- Godoy-Guzmán, C., C. Nuñez, P. Orihuela, A. Campos, and V. Carriel. 2018. "Distribution of Extracellular Matrix Molecules in Human Uterine Tubes During the Menstrual Cycle: A Histological and Immunohistochemical Analysis." *Journal of Anatomy* 233: 73–85.
- Goto, H., A. Inoue, L. Piao, et al. 2021. "Proliferin-1 Ameliorates Cardiotoxin-Related Skeletal Muscle Repair in Mice." *Stem Cells International* 2021: 1–20.
- Guller, A., and A. Igrunkova. 2023. "Engineered Microenvironments for 3D Cell Culture and Regenerative Medicine: Challenges, Advances, and Trends." *Bioengineering* 10: 17. <https://doi.org/10.3390/bioengineering10010017>.
- Han, F., J. Wang, L. Ding, et al. 2020. "Tissue Engineering and Regenerative Medicine: Achievements, Future, and Sustainability in Asia." *Frontiers in Bioengineering and Biotechnology* 8: 83. <https://doi.org/10.3389/fbioe.2020.00083>.
- Hong, X., Y. Yuan, X. Sun, et al. 2018. "Skeletal Extracellular Matrix Supports Cardiac Differentiation of Embryonic Stem Cells: A Potential Scaffold for Engineered Cardiac Tissue." *Cellular Physiology and Biochemistry* 45: 319–331.
- Jin, J., F. Li, C. Fan, Y. Wu, and C. He. 2022. "Elevated Mir-145-5p Is Associated With Skeletal Muscle Dysfunction and Triggers Apoptotic Cell Death in C2C12 Myotubes." *Journal of Muscle Research and Cell Motility* 43: 135–145.
- Juhas, M., N. Abutaleb, J. T. Wang, et al. 2018. "Incorporation of Macrophages Into Engineered Skeletal Muscle Enables Enhanced Muscle Regeneration." *Nature Biomedical Engineering* 2: 942–954.
- Juhas, M., G. C. Engelmayr, A. N. Fontanella, G. M. Palmer, and N. Bursac. 2014. "Biomimetic Engineered Muscle With Capacity for Vascular Integration and Functional Maturation In Vivo." *PNAS* 111: 5508–5513.
- Keshtkar, S., N. Azarpira, and M. H. Ghahremani. 2018. "Mesenchymal Stem Cell-Derived Extracellular Vesicles: Novel Frontiers in Regenerative Medicine." *Stem Cell Research and Therapy* 9: 63. <https://doi.org/10.1186/s13287-018-0791-7>.
- Kohno, S., T. Ueki, T. Abe, et al. 2011. "Rantes Secreted From Macrophages Disturbs Skeletal Muscle Regeneration After Cardiotoxin Injection in Cbl-b-deficient Mice." *Muscle & Nerve* 43: 223–229.
- Li, S., W. Sun, H. Zheng, and F. Tian. 2018. "MicroRNA-145 Accelerates the Inflammatory Reaction Through Activation of NF- κ B Signaling in Atherosclerosis Cells and Mice." *Biomedicine and Pharmacotherapy* 103: 851–857.
- Lin Shiau, S. Y., M. C. Huang, and C. Y. Lee. 1976. "Mechanism of Action of Cobra Cardiotoxin in the Skeletal Muscle." *Journal of Pharmacology and Experimental Therapeutics* 196: 758–770.
- Liu, C., Z. Xia, and J. T. Czernuszka. 2007. "Design and Development of Three-Dimensional Scaffolds for Tissue Engineering." *Chemical Engineering Research and Design* 85: 1051–1064. <https://doi.org/10.1205/cherd06196>.
- Liu, N., A. H. Williams, J. M. Maxeiner, et al. 2012. "MicroRNA-206 Promotes Skeletal Muscle Regeneration and Delays Progression of Duchenne Muscular Dystrophy in Mice." *Journal of Clinical Investigation* 122: 2054–2065.
- Magarotto, F., A. Sgrò, A. H. Dorigo Hochuli, et al. 2021. "Muscle Functional Recovery Is Driven by Extracellular Vesicles Combined With Muscle Extracellular Matrix in a Volumetric Muscle Loss Murine Model." *Biomaterials* 269: 120653.
- Malvicini, R., D. Santa-Cruz, G. De Lazzari, et al. 2022. "Macrophage Bioassay Standardization to Assess the Anti-Inflammatory Activity of Mesenchymal Stromal Cell-Derived Small Extracellular Vesicles." *Cytotherapy* 24: 999–1012.
- Markoutsas, E., K. Mayilsamy, D. Gulick, S. S. Mohapatra, and S. Mohapatra. 2022. "Extracellular Vesicles Derived From Inflammatory-Educated Stem Cells Reverse Brain Inflammation—Implication of miRNAs." *Molecular Therapy* 30: 816–830.
- Mellows, B., R. Mitchell, M. Antonioli, et al. 2017. "Protein and Molecular Characterization of a Clinically Compliant Amniotic Fluid Stem Cell-Derived Extracellular Vesicle Fraction Capable of Accelerating Muscle Regeneration Through Enhancement of Angiogenesis." *Stem Cells and Development* 26: 1316–1333.
- Mitchell, R., B. Mellows, J. Sheard, et al. 2019. "Secretome of Adipose-Derived Mesenchymal Stem Cells Promotes Skeletal Muscle Regeneration Through Synergistic Action of Extracellular Vesicle Cargo and Soluble Proteins." *Stem Cell Research & Therapy* 10: 116.
- Muir, E. M., K. H. Adcock, D. A. Morgenstern, et al. 2002. "Matrix Metalloproteases and Their Inhibitors Are Produced by Overlapping Populations of Activated Astrocytes." *Molecular Brain Research* 100: 103–117. www.elsevier.com/locate/bres.
- Neishabouri, A., A. Soltani Khaboushan, F. Daghigh, A. M. Kajbafzadeh, and M. Majidi Zolbin. 2022. "Decellularization in Tissue Engineering and Regenerative Medicine: Evaluation, Modification, and Application Methods." *Frontiers in Bioengineering and Biotechnology* 10: 805299. <https://doi.org/10.3389/fbioe.2022.805299>.
- Nelson, B. C., M. E. Wintenberg, S. W. Schaffter, and W. N. Vreeland. 2025. "The Need for Standardization of Extracellular Vesicle Characterization Methods." In *Exosomes and Extracellular Vesicles*, 7–49. Springer Nature Switzerland. https://doi.org/10.1007/978-3-031-89270-7_2.
- Nikolova, M. P., and M. S. Chavali. 2019. "Recent Advances in Biomaterials for 3D Scaffolds: A Review." *Bioactive Materials* 4: 271–292.
- O'Brien, F. J. 2011. "Biomaterials & Scaffolds for Tissue Engineering." *Materials Today* 14, no. 3: 88–95. [https://doi.org/10.1016/S1369-7021\(11\)70058-X](https://doi.org/10.1016/S1369-7021(11)70058-X).
- Piccoli, M., C. Trevisan, E. Maghin, C. Franzin, and M. Pozzobon. 2017. *Mouse Skeletal Muscle Decellularization*. Edited by K. Turksen, Vol. 1577: 87–93. Springer New York.
- Quarta, M., M. Cromie, R. Chacon, et al. 2017. "Bioengineered Constructs Combined With Exercise Enhance Stem Cell-Mediated Treatment of Volumetric Muscle Loss." *Nature Communications* 8: 15613.
- Raffa, P., V. Scattolini, M. F. M. Gerli, et al. 2020. "Decellularized Skeletal Muscles Display Neurotrophic Effects in Three-Dimensional Organotypic Cultures." *Stem Cells Translational Medicine* 9: 1233–1243.
- Rey, D. F. V., and J. P. St-Pierre. 2019. "Fabrication Techniques of Tissue Engineering Scaffolds." In *Handbook of Tissue Engineering Scaffolds: Volume One*, 109–125. Elsevier. <https://doi.org/10.1016/B978-0-08-102563-5.00006-X>.
- Reyna, W. E., R. Pichika, D. Ludvig, and E. J. Perreault. 2020. "Efficiency of Skeletal Muscle Decellularization Methods and Their Effects on the Extracellular Matrix." *Journal of Biomechanics* 110: 109961.
- Rezakhaniha, R., A. Agianniotis, J. T. C. Schrauwen, et al. 2012. "Experimental Investigation of Collagen Waviness and Orientation in the Arterial Adventitia Using Confocal Laser Scanning Microscopy." *Biomechanics and Modeling in Mechanobiology* 11: 461–473.
- Riazifar, M., E. J. Pone, J. Lötvall, and W. Zhao. 2017. "Stem Cell Extracellular Vesicles: Extended Messages of Regeneration." *Annual Review of Pharmacology and Toxicology* 57: 125–154. <https://doi.org/10.1146/annurev-pharmtox-061616-030146>.
- Riis, S., A. C. Hansen, L. Johansen, et al. 2020. "Fabrication and Characterization of Extracellular Matrix Scaffolds Obtained From Adipose-Derived Stem Cells." *Methods (San Diego, California)* 171: 68–76.
- Saggiaro, M., S. D'Agostino, A. Gallo, et al. 2022. "A Rhabdomyosarcoma Hydrogel Model to Unveil Cell-Extracellular Matrix Interactions." *Biomaterials Science* 10: 124–137.
- Sandonà, M., S. Consalvi, L. Tucciarone, et al. 2020. "HDAC Inhibitors Tune miRNAs in Extracellular Vesicles of Dystrophic Muscle-Resident Mesenchymal Cells." *Embo Reports* 21: e50863.
- Schindelin, J., I. Arganda-Carreras, E. Frise, et al. 2012. "Fiji: An Open-Source Platform for Biological-Image Analysis." *Nature Methods* 9: 676–682. <https://doi.org/10.1038/nmeth.2019>.

Shin, D. I., Y. J. Jin, S. Noh, H.-W. Yun, D. Y. Park, and B.-H. Min. 2024. "Exosomes Secreted During Myogenic Differentiation of Human Fetal Cartilage-Derived Progenitor Cells Promote Skeletal Muscle Regeneration Through miR-145-5p." *Tissue Engineering and Regenerative Medicine* 21: 487–497.

Sicari, B. M., J. L. Dziki, B. F. Siu, C. J. Medberry, C. L. Dearth, and S. F. Badylak. 2014. "The Promotion of a Constructive Macrophage Phenotype by Solubilized Extracellular Matrix." *Biomaterials* 35: 8605–8612.

Tahamtan, A., M. Teymouri-Rad, B. Nakstad, and V. Salimi. 2018. "Anti-Inflammatory MicroRNAs and Their Potential for Inflammatory Diseases Treatment." *Frontiers in Immunology* 9: 1377. <https://doi.org/10.3389/fimmu.2018.01377>.

Takahashi, H., T. Shimizu, and T. Okano. 2018. "Engineered Human Contractile Myofiber Sheets as a Platform for Studies of Skeletal Muscle Physiology." *Scientific Reports* 8: 13932.

Tidball, J. G., and S. A. Villalta. 2010. "Regulatory Interactions Between Muscle and the Immune System During Muscle Regeneration." *American Journal of Physiology—Regulatory Integrative and Comparative Physiology* 298: R1173–R1187. <https://doi.org/10.1152/ajpregu.00735.2009>.

Todesco, M., S. J. Imran, T. M. Fortunato, et al. 2022. "A New Detergent for the Effective Decellularization of Bovine and Porcine Pericardia." *Biomimetics* 7: 104.

Trevisan, C., M. E. A. Fallas, E. Maghin, et al. 2019. "Generation of a Functioning and Self-Renewing Diaphragmatic Muscle Construct." *Stem Cells Translational Medicine* 8: 858–869.

Urciuolo, A., L. Urbani, S. Perin, et al. 2018. "Decellularised Skeletal Muscles Allow Functional Muscle Regeneration by Promoting Host Cell Migration." *Scientific Reports* 8: 8398.

Wang, B., A. Borazjani, M. Tahai, et al. 2010. "Fabrication of Cardiac Patch With Decellularized Porcine Myocardial Scaffold and Bone Marrow Mononuclear Cells." *Journal of Biomedical Materials Research Part A* 94: 1100–1110.

Wang, Y., J. Lu, and Y. Liu. 2022. "Skeletal Muscle Regeneration in Cardiotoxin-Induced Muscle Injury Models." *International Journal of Molecular Sciences* 23: 13380. <https://doi.org/10.3390/ijms232113380>.

Welsh, J. A., D. C. I. Goberdhan, L. O'Driscoll, et al. 2024. "Minimal Information for Studies of Extracellular Vesicles (MISEV2023): From Basic to Advanced Approaches." *Journal of Extracellular Vesicles* 13: e12404.

Wu, S., H. Li, H. Yang, X. Zhang, Z. Li, and S. Xu. 2011. "Quantitative Analysis on Collagen Morphology in Aging Skin Based on Multiphoton Microscopy." *Journal of Biomedical Optics* 16: 040502.

Yang, J., Y. Gu, X. Huang, A. Shen, and C. Cheng. 2011. "Dynamic Changes of ICAM-1 Expression in Peripheral Nervous System Following Sciatic Nerve Injury." *Neurological Research* 33: 75–83.

Zanotti, S., S. Gibertini, M. Curcio, et al. 2015. "Opposing Roles of miR-21 and miR-29 in the Progression of Fibrosis in Duchenne Muscular Dystrophy." *Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease* 1852: 1451–1464.

Zaramella, A., A. H. Dorigo Hochuli, M. Duci, et al. 2025. "Three-Dimensional Multicellular Layer Structure: An Advanced In Vitro Model for Studying Inflammatory Bowel Diseases." *Scientific Reports* 15: 40718.

Zhang, Z., K. Deng, Z. Kang, F. Wang, and Y. Fan. 2022. "MicroRNA Profiling Reveals miR-145-5p Inhibits Goat Myoblast Differentiation by Targeting the Coding Domain Sequence of USP13." *FASEB Journal* 36: e22370.

Zong, L., P. Huang, Q. Song, and Y. Kang. 2021. "Bone Marrow Mesenchymal Stem Cells-Secreted Exosomal H19 Modulates Lipopolysaccharides-Stimulated Microglial M1/M2 Polarization and Alleviates Inflammation-Mediated Neurotoxicity." *American Journal of Translational Research* 13: 935–951. www.ajtr.org.

Supporting Information

Additional supporting information can be found online in the Supporting Information section.

Supplementary Figures: jev270237-sup-0001-

SuppMat.docx **Supplementary Video:** jev270237-

sup-0002-VideoS1.mov **Supplementary Materials:**

jev270237-sup-0003-SuppMat.xlsx